PhRMA Offers “No Reasonable Expert” Standard For Addressing Fraud Charges
PhRMA is backing former InterMune CEO W. Scott Harkonen in his appeal of a fraud conviction for making false statements about Actimmune in a press release. The association argues that he expressed a scientific view that is protected from prosecution under the First Amendment.
You may also be interested in...
Pfizer, Cephalon and former InterMune CEO Scott Harkonen will find no relief from the high court.
Federal prosecutors say they will not pursue False Claims Act cases in which off-label use is the standard of care and note that the Caronia decision will have little impact on investigations; First Amendment defense fails in Par and Harkonen cases.
Par Pharmaceutical Inc.’s First Amendment suit against FDA offers a new approach to battling government allegations of off-label marketing.